The Bengaluru-based anti-diabetes care pharma company Micro Labs Ltd. on Thursday announced the launching of a drug for managing low blood sugar (hypoglycaemic) under the brand name 'Hypotab', reports said.
The company said the dextrose drug formulation is targeted at type 2 diabetes patients, who encounter hypoglycaemia and patients with type 1 diabetes on insulin more prone to develop it.
Senior Vice-President - Marketing & Sales, said Dextrose was the simple form of carbohydrate for rapid restoration of normal blood glucose levels.
Micro Labs has 13 oral formulation plants and four overseas offices. It has made use of "ABMAX technology" for the manufacture of Hypotab which, the company said, offers 20 micron particle size for faster absorption and quick results.
"Hypotab is the first standardized therapy for hypoglycaemia and comes in 4s packing (four chewable tablets of four gms each per strip priced at Rs seven) which is easy to carry in the pocket," he added.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.